Apr 30, 02:26 PM

FTC Targets Ozempic Patents to Boost Generic Drug Competition

The Federal Trade Commission (FTC) is intensifying its scrutiny on the pharmaceutical industry, particularly targeting patent listings of popular drugs like Novo Nordisk's Ozempic and Victoza. The FTC's actions, which include sending warnings to pharmaceutical companies about 'junk' patents, aim to hasten the entry of generic competitors into the market. This move could potentially make Ozempic, a leading diabetes therapy that's also gaining traction as a weight-loss drug, as common and affordable as generic drugs. Concurrently, supplement stores such as GNC and the Vitamin Shoppe are capitalizing on the growing demand for weight-loss drugs by redesigning store layouts and enhancing marketing strategies to attract consumers interested in products like Ozempic and Wegovy.